| Rite Aid Pharmacy # 11219 | |
| 1316 Mount Hermon Rd, Salisbury, Maryland 21804 | |
| (410) 749-0205 |
| Name | Rite Aid Pharmacy # 11219 |
|---|---|
| Organization Name | Thrift Drug Inc |
| Location | 1316 Mount Hermon Rd, Salisbury, Maryland 21804 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (410) 749-0205 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A landmark trial showed that the replacement of the standard malaria drug Quinine with the newer drug Artesunate for children with severe malaria could save 100,000 lives a year. The World Health Organisation (WHO) recommended that artesunate derived from a Chinese plant called sweet wormwood, replace the four-century-old remedy of quinine for treating severe malaria in adults in 2006. Similar recommendations were not made for children with further trial results pending.
In an ongoing effort to mirror the ability of biological tissues to respond rapidly and appropriately to changing environments, scientists from the McGowan Institute for Regenerative Medicine have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins. They described the findings recently in Biomaterials.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
People with psychosis report a marked excess of victimising experiences, many of which occurred during childhood, according to a new study.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
› Verified 3 days ago
| NPI Number | 1467551663 |
| Organization Name | THRIFT DRUG INC |
| Doing Business As | RITE AID PHARMACY 11219 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1316 Mount Hermon Road, Salisbury, MD 21804 |
| Phone Number | 410-749-0205 |
News Archive
A landmark trial showed that the replacement of the standard malaria drug Quinine with the newer drug Artesunate for children with severe malaria could save 100,000 lives a year. The World Health Organisation (WHO) recommended that artesunate derived from a Chinese plant called sweet wormwood, replace the four-century-old remedy of quinine for treating severe malaria in adults in 2006. Similar recommendations were not made for children with further trial results pending.
In an ongoing effort to mirror the ability of biological tissues to respond rapidly and appropriately to changing environments, scientists from the McGowan Institute for Regenerative Medicine have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins. They described the findings recently in Biomaterials.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
People with psychosis report a marked excess of victimising experiences, many of which occurred during childhood, according to a new study.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
› Verified 3 days ago
News Archive
A landmark trial showed that the replacement of the standard malaria drug Quinine with the newer drug Artesunate for children with severe malaria could save 100,000 lives a year. The World Health Organisation (WHO) recommended that artesunate derived from a Chinese plant called sweet wormwood, replace the four-century-old remedy of quinine for treating severe malaria in adults in 2006. Similar recommendations were not made for children with further trial results pending.
In an ongoing effort to mirror the ability of biological tissues to respond rapidly and appropriately to changing environments, scientists from the McGowan Institute for Regenerative Medicine have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins. They described the findings recently in Biomaterials.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
People with psychosis report a marked excess of victimising experiences, many of which occurred during childhood, according to a new study.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
› Verified 3 days ago
Rite Aid Pharmacy #04920 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1208 Parsons Rd, Salisbury, Maryland 21801 Phone: (410) 543-8180 | |
Rite Aid Pharmacy 11218 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 833 S Salisbury Blvd, Salisbury, Maryland 21801 Phone: (443) 260-0722 | |
Lincare Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 119 Naylor Mill Rd, Salisbury, Maryland 21801 Phone: (410) 219-5145 | |
Rite Aid Pharmacy # 11219 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1316 Mount Hermon Rd, Salisbury, Maryland 21804 Phone: (410) 749-0205 | |
American Homepatient Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1024 S Tower Dr, Salisbury, Maryland 21804 Phone: (410) 742-3711 |